![](https://inditecommunications.com/wp-content/uploads/2023/08/Pembrolizumab-plus-lenvatinib-as-first-line-therapy-for-advanced-non-clear-cell-renal-cell-carcinoma-KEYNOTE-B61_2023_08_16.jpg)
16 Aug Pembrolizumab plus Lenvatinib as First-line Therapy for Advanced Non-clear-cell Renal Cell Carcinoma (KEYNOTE-B61)
In the KEYNOTE-B61 phase 2, single-arm study, patients with previously untreated stage IV non-clear-cell renal cell carcinoma treated with pembrolizumab plus lenvatinib showed a confirmed objective response (49%; 95% CI 41-57), including confirmed complete response (6%) and partial response (44%). The most common Grade 3-4 treatment-related adverse events were hypertension (23%), proteinuria (4%), and stomatitis (4%). (Albiges L, et al. Lancet Oncol. August, 2023)
#oncologyresearch #clinicalresearch #clinicaldevelopment
Sorry, the comment form is closed at this time.